An observational study in Aortic Valve Sclerosis, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2025-05-11.
Sponsored by Sohag University · Observational
the goal of the study to identify the relation between aortic valve sclerosis and severity of coronary heart disease by performing transthoracic echo Doppler study for severity of aortic valve sclerosis in patient will undergo coronary angiography with calculation of syntax score as a tool for severity of coronary heart disease.
Sohag University is the lead sponsor of 1,220 studies on the registry; 629 are open to participants now.
Counted across the registry records on this site, refreshed daily.
100a patients from both sex who are diagnosed to be aortic valve sclerosis and will undergo coronary angiography in Sohag university hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Aortic valve sclerosis severity study be transthoracic echo doppler
relation between Aortic valve sclerosis and severity of coronary heart disease
significant relation between severity of aortic valve sclerosis assessed by trans thoracic echo doppler quantified by Chandra et al on a scale of 0 to 3. 0 (no involvement). 1. mild (minor involvement of one leaflet) 2. moderate (minor involvement of two leaflets or extensive involvement of one leaflet. 3. severe (extensive involvement of two leaflets or involvement of all three leaflets). And severity of coronary heart disease in patients already underwent or planned to perform coronary angiography quantified by syntax score considering score above 20 as severe coronary heart disease.
Time frame: 6 months
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.